Colorectal Cancer Market, By Cancer Type (Colon Cancer and Rectal Cancer), By Drug Class (Chemotherapy Agents (5-Fluorouracil (5-FU), Capecitabine, Irinotecan, Others (Oxaliplatin, Leucovorin etc.)), Targeted Therapies (Bevacizumab, Encorafenib, Fruquintinib, Cetuximab, Regorafenib, Others (Trifluridine/Tipiracil) Immunotherapies, (Nivolumab, Pembrolizumab, and Others (Ipilimumab) Combination Therapy (For e.g. Encorafenib, Cetuxima, mFOLFOX6, etc.)), By Type (Metastatic and Non-Metastatic), By Stage of Cancer (Stage I, Stage II, Stage III, and Stage IV), By Route of Administration (Oral and Parenteral), By Age Group (Adult, Pediatric, and Geriatric), By Gender (Male and Female), By End User (Hospitals and Cancer Centers, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, and Research and Academic Institutes), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa)